ITGAM and central nervous system cancer: Immunofluorescence imaging of a checkpoint inhibitor-resistant murine glioma model showed a reduction in CD11b+ myeloid cells when treated with an antagonist of CCR2, a chemokine involved in inflammatory myeloid cell infiltration in the glioma microenvironment [62].